1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
2
|
Afuwape OO, Irabor DO, Ladipo JK and
Ayandipo B: A Review of the Current Profile of Gastric Cancer
Presentation in the University College Hospital Ibadan, a Tertiary
Health Care Institution in the Tropics. J Gastrointest Cancer. Feb,
2011.(Epub ahead of print).
|
3
|
Herszényi L and Tulassay Z: Epidemiology
of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci.
14:249–258. 2010.
|
4
|
Wang W, Li YF, Sun XW, et al: Prognosis of
980 patients with gastric cancer after surgical resection. Chin J
Cancer. 29:923–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Arkenau HT: Gastric cancer in the era of
molecularly targeted agents: current drug development strategies. J
Cancer Res Clin Oncol. 135:855–866. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Aarnio M, Sankila R, Pukkala E, et al:
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int
J Cancer. 81:214–218. 1999. View Article : Google Scholar : PubMed/NCBI
|
7
|
Goecke T, Schulmann K, Engel C, et al:
Genotype-phenotype comparison of German MLH1 and MSH2 mutation
carriers clinically affected with Lynch syndrome: a report by the
German HNPCC consortium. J Clin Oncol. 24:4285–4292. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Abdel-Rahman WM, Mecklin JP and Peltomaki
P: The genetics of HNPCC: application to diagnosis and screening.
Crit Rev Oncol Hematol. 58:208–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Liu T: Mutational screening of hMLH1 and
hMSH2 that confer inherited colorectal cancer susceptibility using
denature gradient gel electrophoresis (DGGE). Methods Mol Biol.
653:193–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Vasen HF, Stormorken A, Menko FH, et al:
MSH2 mutation carriers are at higher risk of cancer than MLH1
mutation carriers: a study of hereditary nonpolyposis colorectal
cancer families. J Clin Oncol. 19:4074–4080. 2001.PubMed/NCBI
|
11
|
Haghighi MM, Javadi GR, Parivar K,
Milanizadeh S, Zali N, Fatemi SR and Zali MR: Frequent MSI
mononucleotide markers for diagnosis of hereditary nonpolyposis
colorectal cancer. Asian Pac J Cancer Prev. 11:1033–1035.
2010.PubMed/NCBI
|
12
|
Scheuner MT, McNeel TS and Freedman AN:
Population prevalence of familial cancer and common hereditary
cancer syndromes. The 2005 California Health Interview Survey.
Genet Med. 12:726–735. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Power DG, Gloglowski E and Lipkin SM:
Clinical genetics of hereditary colorectal cancer. Hematol Oncol
Clin North Am. 24:837–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Sheng X, Zhou HH, Zhou XY, et al: Germline
mutation analysis of hPMS2 gene in Chinese families with hereditary
nonpolyposis colorectal cancer. World J Gastroenterol.
16:3847–3852. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Corso G, Marrelli D and Roviello F:
Familial gastric cancer: update for practice management. Fam
Cancer. 10:391–396. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yamasaki Y, Matsushima M, Tanaka H, et al:
Patient with eight metachronous gastrointestinal cancers thought to
be hereditary nonpolyposis colorectal cancer (HNPCC). Intern Med.
49:209–213. 2010. View Article : Google Scholar
|
17
|
Capelle LG, Van Grieken NC, Lingsma HF, et
al: Risk and epidemiological time trends of gastric cancer in Lynch
syndrome carriers in the Netherlands. Gastroenterology.
138:487–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Xie J, Guillemette S, Peng M, Gilbert C,
Buermeyer A and Cantor SB.: An MLH1 mutation links BACH1/FANCJ to
colon cancer, signaling, and insight toward directed therapy.
Cancer Prev Res (Phila). 3:1409–1416. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
van Roon EH, van Puijenbroek M, Middeldorp
A, et al: Early onset MSI-H colon cancer with MLH1 promoter
methylation, is there a genetic predisposition? BMC Cancer.
10:1802010.PubMed/NCBI
|
20
|
Allan JM, Shorto J, Adlard J, et al: MLH1
-93G>A promoter polymorphism and risk of mismatch repair
deficient colorectal cancer. Int J Cancer. 123:2456–2459. 2008.
|
21
|
Park SH, Lee GY, Jeon HS, et al:
-93G-->A polymorphism of hMLH1 and risk of primary lung cancer.
Int J Cancer. 112:678–682. 2004.
|
22
|
Wang H, Wang Y, Liu H, et al:
Polymorphisms in hMLH1 and risk of early-onset lung cancer in a
southeast Chinese population. Lung Cancer. 59:164–170. 2008.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Vietri MT, Riegler G, De Paola M, et al:
I219V polymorphism in hMLH1 gene in patients affected with
ulcerative colitis. Genet Test Mol Biomarkers. 13:193–197. 2009.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Trojan J, Zeuzem S, Randolph A, et al:
Functional analysis of hMLH1 variants and HNPCC-related mutations
using a human expression system. Gastroenterology. 122:211–219.
2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bellacosa A: Functional interactions and
signaling properties of mammalian DNA mismatch repair proteins.
Cell Death Differ. 8:1076–1092. 2001. View Article : Google Scholar : PubMed/NCBI
|
26
|
Jung CY, Choi JE, Park JM, et al:
Polymorphisms in the hMSH2 gene and the risk of primary lung
cancer. Cancer Epidemiol Biomarkers Prev. 15:762–768. 2006.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Worrillow LJ, Travis LB, Smith AG, Sara R,
Andrew JS and Christopher PW: An intron splice acceptor
polymorphism in hMSH2 and risk of leukemia after treatment with
chemotherapeutic alkylating agents. Clin Cancer Res. 9:3012–3020.
2003.PubMed/NCBI
|
28
|
Paz-y-Miño C, Pérez JC, Fiallo BF and
Leone PE: A polymorphism in the hMSH2 gene (gIVS12-6T>C)
associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet.
133:29–33. 2002.
|
29
|
Palicio M, Blanco I, Tórtola S, et al:
Intron splice acceptor site polymorphism in the hMSH2 gene in
sporadic and familial colorectal cancer. Br J Cancer. 82:535–537.
2000. View Article : Google Scholar : PubMed/NCBI
|
30
|
Goessl C, Plaschke J, Pistorius S, Hahn M,
Frank S and Hampl M: An intronic germline transition in the HNPCC
gene hMSH2 is associated with sporadic colorectal cancer. Eur J
Cancer. 33:1869–1874. 1997. View Article : Google Scholar : PubMed/NCBI
|
31
|
Brentnall TA, Rubin CE, Crispin DA, et al:
A germline substitution in the human MSH2 gene is associated with
high-grade dysplasia and cancer in ulcerative colitis.
Gastroenterology. 109:151–155. 1995. View Article : Google Scholar : PubMed/NCBI
|
32
|
Cheng H, Sun N, Sun X, et al:
Polymorphisms in hMSH2 and hMLH1 and response to platinum-based
chemotherapy in advanced non-small-cell lung cancer patients. Acta
Biochim Biophys Sin (Shanghai). 42:311–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Mrkonjic M, Raptis S, Green RC, et al:
MSH2 118T>C and MSH6 159C>T promoter polymorphisms and the
risk of colorectal cancer. Carcinogenesis. 28:2575–2580. 2007.
|
34
|
Shin KH, Shin JH, Kim JH and Park JG:
Mutational analysis of promoters of mismatch repair genes hMSH2 and
hMLH1 in hereditary nonpolyposis colorectal cancer and early onset
colorectal cancer patients: identification of three novel germ-line
mutations in promoter of the hMSH2 gene. Cancer Res. 62:38–42.
2002.
|
35
|
Vasen HF, Watson P, Mecklin JP and Lynch
HT: New clinical criteria for hereditary nonpolyposis colorectal
cancer (HNPCC, Lynch syndrome) proposed by the International
Collaborative group on HNPCC. Gastroenterology. 116:1453–1456.
1999. View Article : Google Scholar
|